The intent of the program is discovery of principles of infectious disease (re)emergence and transmission and testing mathematical or computational models that elucidate infectious disease systems.

This supports research on the ecological, evolutionary, organismal, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative, mathematical, or computational understanding of pathogen transmission dynamics.

Letter of intent due (30 days prior to due date). NOFO expires 4/16/27. NLM wishes to accelerate access to, and availability of, secure, complete datasets and computational models that can serve as the basis for transformative biomedical discoveries.

Limited submission. DMREF will support activities that significantly accelerate the materials discovery-to-use timeline by building the fundamental knowledge base needed to advance the design, development, or manufacturability of materials with desirable properties or functionality.

Three times per year, the OSU Advantage Accelerator seeks technology-based projects in any discipline that will move OSU-owned technologies closer to commercialization. Projects should require $15,000 or less of Accelerator Innovation and Development (AID) funding to achieve an important milestone(s) connected to commercialization.

Daiichi Sankyo is seeking diseases that can be treated effectively by inhibiting one or two proteases. The target protease(s) do not have to be expressed only extracellularly, but therapeutic efficacy must be expected by inhibiting the protease outside the cell.

Halo announces 19 new collaboration opportunities with industry. These range from chemistry application to gene therapy to agriculture.

Daiichi Sankyo is seeking innovative research projects that can evaluate the efficacy of gene therapies targeting specific genes in chromosomal abnormalities. Their primary interest is in research focused on Down syndrome (trisomy 21), but other conditions such as trisomy 13, trisomy 18, as well as 5p- and 4p- syndromes are also within the scope.

The sponsor is seeking test methods that simulate long-term microbial exposure and its impact on both coatings and substrates, to better predict the performance of protective coatings and their ability to resist microbially induced corrosion and/or biodeterioration over extended periods.

Daiichi Sankyo is seeking innovative research projects that can identify and explore novel targets for gene therapy, particularly in CNS (central nervous system) and CVM (cardiovascular and metabolism) related diseases.